BDRX supply chain intelligence for Biodexa Pharmaceuticals Plc: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Biodexa Pharmaceuticals Plc (BDRX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CGON | CG Oncology, Inc. | 72% | l lawsuits challenging state authority to regulate prescription drug payment limits. Furthermore, in December 2020, the U.S. Supreme Court held unanimously that federal law does not preempt the state… |
| CGON | CG Oncology, Inc. | 72% | Reciprocal relationship from CGON graph: Reciprocal relationship from BDRX graph: l lawsuits challenging state authority to regulate prescription drug payment limits. Furthermore, in December 2020, t… |
| CNSP | CNS Pharmaceuticals, Inc. | 72% | ther companies in the sustained release space include Medincell S.A., InnoCore Technologies BV, GP Pharm, S.A., Peptron, Inc., and Nanomi B.V. From a technology perspective, we believe other companie… |
| CNSP | CNS Pharmaceuticals, Inc. | 72% | Reciprocal relationship from CNSP graph: Reciprocal relationship from BDRX graph: ther companies in the sustained release space include Medincell S.A., InnoCore Technologies BV, GP Pharm, S.A., Peptr… |
| CRSP | CRISPR Therapeutics AG | 72% | Reciprocal relationship from CRSP graph: Reciprocal relationship from BDRX graph: ll therapies by Vertex Pharmaceuticals, Inc. and CRISPR Therapeutics AG and SAB Biotherapeutics, Inc. is developing a… |
| CRSP | CRISPR Therapeutics AG | 72% | ll therapies by Vertex Pharmaceuticals, Inc. and CRISPR Therapeutics AG and SAB Biotherapeutics, Inc. is developing an immunotherapeutic. The JDRF T1D Fund has invested in approximately 30 private co… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from BDRX graph: with the objectives of safeguarding the health and wellbeing of our staff members and monitoring the impact on our ven… |
| JNJ | Johnson & Johnson | 72% | with the objectives of safeguarding the health and wellbeing of our staff members and monitoring the impact on our vendors and collaborators. Beginning in mid-March 2020, our employees primarily work… |
| MNKD | MannKind Corporation | 72% | ticles like Midatech GNPs are emerging as the fastest growing sector within the nanomedicine market. The speed and nature of technological change means that physical science is always evolving and ne… |
| MNKD | MannKind Corporation | 72% | Reciprocal relationship from MNKD graph: Reciprocal relationship from BDRX graph: ticles like Midatech GNPs are emerging as the fastest growing sector within the nanomedicine market. The speed and na… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from NVSE… |
| NVSEF | Novartis AG | 72% | f these include the following: • We have experienced some delays in our clinical trials, in particular our Phase I trials of MTX110 in diffuse intrinsic pontine glioma, or DIPG, at Columbia Universit… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from BDRX graph: ities, in which the Licensees will be responsible for developing and commercializing certain of our key pipeline pro… |
| ORANY | ORANY | 72% | ities, in which the Licensees will be responsible for developing and commercializing certain of our key pipeline products in China and certain other southeast Asia countries. For more information on … |
| PSTV | Plus Therapeutics, Inc. | 72% | ll therapies by Vertex Pharmaceuticals, Inc. and CRISPR Therapeutics AG and SAB Biotherapeutics, Inc. is developing an immunotherapeutic. The JDRF T1D Fund has invested in approximately 30 private co… |
| PSTV | Plus Therapeutics, Inc. | 72% | Reciprocal relationship from PSTV graph: Reciprocal relationship from BDRX graph: ll therapies by Vertex Pharmaceuticals, Inc. and CRISPR Therapeutics AG and SAB Biotherapeutics, Inc. is developing a… |
| RXRX | Recursion Pharmaceuticals, Inc. | 72% | l lawsuits challenging state authority to regulate prescription drug payment limits. Furthermore, in December 2020, the U.S. Supreme Court held unanimously that federal law does not preempt the state… |
| RXRX | Recursion Pharmaceuticals, Inc. | 72% | Reciprocal relationship from RXRX graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from RXRX graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from RXRX g… |
| SABS | SAB Biotherapeutics, Inc. | 72% | Reciprocal relationship from SABS graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from SABS graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from SABS g… |
| SABSW | SABSW | 72% | ll therapies by Vertex Pharmaceuticals, Inc. and CRISPR Therapeutics AG and SAB Biotherapeutics, Inc. is developing an immunotherapeutic. The JDRF T1D Fund has invested in approximately 30 private co… |
| SABSW | SABSW | 72% | Reciprocal relationship from SABSW graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from SABSW graph: Reciprocal relationship from BDRX graph: ll therapies by Vertex Pharmaceut… |
| SNYNF | Sanofi | 72% | ticles like Midatech GNPs are emerging as the fastest growing sector within the nanomedicine market. The speed and nature of technological change means that physical science is always evolving and ne… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from BDRX graph: ticles like Midatech GNPs are eme… |
| TARA | Protara Therapeutics, Inc. | 72% | l lawsuits challenging state authority to regulate prescription drug payment limits. Furthermore, in December 2020, the U.S. Supreme Court held unanimously that federal law does not preempt the state… |
| TARA | Protara Therapeutics, Inc. | 72% | Reciprocal relationship from TARA graph: Reciprocal relationship from BDRX graph: l lawsuits challenging state authority to regulate prescription drug payment limits. Furthermore, in December 2020, t… |
| TPST | Tempest Therapeutics, Inc. | 72% | Reciprocal relationship from TPST graph: Reciprocal relationship from BDRX graph: sive informational disclosures related to patients’ coverage and benefits; and to accept only bona fide service fees … |
| TPST | Tempest Therapeutics, Inc. | 72% | sive informational disclosures related to patients’ coverage and benefits; and to accept only bona fide service fees from drug companies when providing services under Medicare Part D. The Department … |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CNSP | CNS Pharmaceuticals, Inc. | 72% | , contraindications or other safety information, including boxed warnings; • suspend, vary or withdraw regulatory approval; • require additional post-market clinical trials to assess the safety of th… |
| CNSP | CNS Pharmaceuticals, Inc. | 72% | Reciprocal relationship from CNSP graph: Reciprocal relationship from BDRX graph: , contraindications or other safety information, including boxed warnings; • suspend, vary or withdraw regulatory app… |
| COGT | Cogent Biosciences, Inc. | 72% | ddition of additional warnings, contraindications or other safety information, including boxed warnings; · suspend, vary or withdraw regulatory approval; · require additional post-market clinical tri… |
| COGT | Cogent Biosciences, Inc. | 72% | Reciprocal relationship from COGT graph: Reciprocal relationship from BDRX graph: ddition of additional warnings, contraindications or other safety information, including boxed warnings; · suspend, v… |
| CRSP | CRISPR Therapeutics AG | 72% | ddition of additional warnings, contraindications or other safety information, including boxed warnings; · suspend, vary or withdraw regulatory approval; · require additional post-market clinical tri… |
| CRSP | CRISPR Therapeutics AG | 72% | Reciprocal relationship from CRSP graph: Reciprocal relationship from BDRX graph: ddition of additional warnings, contraindications or other safety information, including boxed warnings; · suspend, v… |
| GSK | GSK plc | 72% | Reciprocal relationship from GSK graph: Reciprocal relationship from BDRX graph: ddition of additional warnings, contraindications or other safety information, including boxed warnings; · suspend, va… |
| GSK | GSK plc | 72% | ddition of additional warnings, contraindications or other safety information, including boxed warnings; · suspend, vary or withdraw regulatory approval; · require additional post-market clinical tri… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from JNJ grap… |
| JNJ | Johnson & Johnson | 72% | , contraindications or other safety information, including boxed warnings; • suspend, vary or withdraw regulatory approval; • require additional post-market clinical trials to assess the safety of th… |
| MANU | Manchester | 72% | ive award is recognized as an expense over the requisite service period of the award, which is usually the vesting period. Compensation expense is recognized over the vesting period using the straigh… |
| MANU | Manchester | 72% | Reciprocal relationship from MANU graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from MANU graph: Reciprocal relationship from BDRX graph: ive award is recognized as an expen… |
| MNKD | MannKind Corporation | 72% | e downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In ad… |
| MNKD | MannKind Corporation | 72% | Reciprocal relationship from MNKD graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from MNKD graph: Reciprocal relationship from BDRX graph: e downward pressure on health care … |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from BDRX graph: irst three years following the effective time of the CMS License Agreement (together the “Products”) to develop and … |
| NVSEF | Novartis AG | 72% | irst three years following the effective time of the CMS License Agreement (together the “Products”) to develop and commercialize the Products in China, including Macau, Hong Kong and Taiwan, with th… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from BDRX graph: following: · concluding a license… |
| ORANY | ORANY | 72% | following: · concluding a license agreement with a third party in respect of any of the intellectual property rights comprising the subject matter of the agreement; · demonstrating therapeutic and/or… |
| PRGO | Perrigo Company plc | 72% | Reciprocal relationship from PRGO graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from PRGO graph: Reciprocal relationship from BDRX graph: t, referred to as API, cGMP, facili… |
| PRGO | Perrigo Company plc | 72% | t, referred to as API, cGMP, facility of its kind in Europe. The facility is licensed to produce sterile material for use in human clinical trials and is capable of manufacturing licensed products. F… |
| RXRX | Recursion Pharmaceuticals, Inc. | 72% | ddition of additional warnings, contraindications or other safety information, including boxed warnings; · suspend, vary or withdraw regulatory approval; · require additional post-market clinical tri… |
| RXRX | Recursion Pharmaceuticals, Inc. | 72% | Reciprocal relationship from RXRX graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from RXRX graph: Reciprocal relationship from BDRX graph: ddition of additional warnings, con… |
| SABS | SAB Biotherapeutics, Inc. | 72% | ddition of additional warnings, contraindications or other safety information, including boxed warnings; · suspend, vary or withdraw regulatory approval; · require additional post-market clinical tri… |
| SABS | SAB Biotherapeutics, Inc. | 72% | Reciprocal relationship from SABS graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from SABS graph: Reciprocal relationship from BDRX graph: ddition of additional warnings, con… |
| SLN | Silence Therapeutics plc | 72% | ive award is recognized as an expense over the requisite service period of the award, which is usually the vesting period. Compensation expense is recognized over the vesting period using the straigh… |
| SLN | Silence Therapeutics plc | 72% | Reciprocal relationship from SLN graph: Reciprocal relationship from BDRX graph: ive award is recognized as an expense over the requisite service period of the award, which is usually the vesting per… |
| SNYNF | Sanofi | 72% | e downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In ad… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from BDRX graph: e downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a resul… |
| TPST | Tempest Therapeutics, Inc. | 72% | Reciprocal relationship from TPST graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from TPST graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from TPST g… |
| TPST | Tempest Therapeutics, Inc. | 72% | ddition of additional warnings, contraindications or other safety information, including boxed warnings; · suspend, vary or withdraw regulatory approval; · require additional post-market clinical tri… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| BDRX-DEBT | Debt stack $82,054 | 90% | Market cache reports total debt of $82,054. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| BDRX-OWNER-SABBY-MANAGEMENT-LLC | Sabby Management, LLC | 95% | 13F/ownership overlay lists Sabby Management, LLC; shares held 38,132; ownership 5.11%; value $168,543; as of 2025-12-31. |
| BDRX-OWNER-SBI-SECURITIES-CO-LTD | SBI Securities Co., Ltd. | 95% | 13F/ownership overlay lists SBI Securities Co., Ltd.; shares held 151; ownership 0.02%; value $667; as of 2026-03-31. |
| BDRX-OWNER-HILTON-HEAD-CAPITAL-PARTNERS-LLC | Hilton Head Capital Partners, LLC | 95% | 13F/ownership overlay lists Hilton Head Capital Partners, LLC; shares held 6; value $26; as of 2026-03-31. |
| BDRX-OWNER-RHUMBLINE-ADVISERS | Rhumbline Advisers | 95% | 13F/ownership overlay lists Rhumbline Advisers; shares held 5; value $22; as of 2025-12-31. |
| BDRX-OWNER-ARMISTICE-CAPITAL-LLC | Armistice Capital, LLC | 95% | 13F/ownership overlay lists Armistice Capital, LLC; shares held 20,000; ownership 2.68%; value $88,400; as of 2025-12-31. |
| BDRX-OWNER-GAMMA-INVESTING-LLC | Gamma Investing LLC | 95% | 13F/ownership overlay lists Gamma Investing LLC; shares held 2,756; ownership 0.37%; value $12,181; as of 2026-03-31. |
| BDRX-OWNER-HRT-FINANCIAL-LP | HRT Financial LP | 95% | 13F/ownership overlay lists HRT Financial LP; shares held 2,117; ownership 0.28%; value $9,357; as of 2025-12-31. |
| BDRX-OWNER-UBS-GROUP-AG | UBS Group AG | 95% | 13F/ownership overlay lists UBS Group AG; shares held 25; value $110; as of 2026-03-31. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CGON | CG Oncology, Inc. | 100.00 | 1 | ['supplier'] |
| CRSP | CRISPR Therapeutics AG | 100.00 | 1 | ['customer', 'supplier'] |
| CBAN | Colony Bankcorp, Inc. | 100.00 | 2 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 2 | |
| BCAX | Bicara Therapeutics Inc. | 100.00 | 2 | |
| SABSW | SAB Biotherapeutics, Inc. | 100.00 | 1 | ['supplier'] |
| DEO | Diageo plc | 100.00 | 2 | |
| RYAOF | Ryanair Holdings plc | 100.00 | 2 | |
| CNSP | CNS Pharmaceuticals, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| ORANY | ORANGE | 100.00 | 1 | ['customer', 'supplier'] |
| BANL | CBL International Limited | 100.00 | 2 | |
| EBS | Emergent BioSolutions Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| SDGR | Schrödinger, Inc. | 100.00 | 2 | |
| AUGO | Aura Minerals Inc. | 100.00 | 2 | |
| ALGM | Allegro MicroSystems, Inc. | 100.00 | 2 | |
| BNRG | Brenmiller Energy Ltd | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| ALCY | Alchemy Investments Acquisition Corp 1 | 100.00 | 2 | |
| AAUAF | Almaden Minerals Ltd. | 100.00 | 2 |